TY - JOUR
T1 - Excess burden of respiratory and abdominal conditions following COVID-19 infections during the ancestral and Delta variant periods in the United States
T2 - An EHR-based cohort study from the RECOVER program
AU - RECOVER Consortium
AU - Varma, Jay K.
AU - Zang, Chengxi
AU - Carton, Thomas W.
AU - Block, Jason P.
AU - Khullar, Dhruv J.
AU - Zhang, Yongkang
AU - Weiner, Mark G.
AU - Rothman, Russell L.
AU - Schenck, Edward J.
AU - Xu, Zhenxing
AU - Lyman, Kristin
AU - Bian, Jiang
AU - Xu, Jie
AU - Shenkman, Elizabeth A.
AU - Maughan, Christine
AU - Castro-Baucom, Leah
AU - O'Brien, Lisa
AU - Wang, Fei
AU - Kaushal, Rainu
AU - Mirhaji, Parsa
AU - Jhaveri, Ravi
AU - Forrest, Chris
AU - Morizono, Hiroki
AU - Pajor, Nathan
AU - Sengupta, Soumitra
AU - Jones, Schuyler
AU - Horne, Benjamin D.
AU - Carton, Tom
AU - Taylor, Bradley
AU - Lenert, Leslie
AU - Mosa, Abu
AU - Horowitz, Carol
AU - Kelleher, Kelly
AU - Bunnell, H. Timothy
AU - Liebovitz, David
AU - Blecker, Saul
AU - Sills, Marion
AU - Fort, Dan
AU - Hogan, William
AU - Oxner, Asa
AU - Kamaleswaran, Rishi
AU - Tsinoremas, Nick
AU - Salyakina, Daria
AU - Chuang, Cynthia
AU - Christakis, Dimitri
AU - Paranjape, Anuradha
AU - Fernandez, Soledad
AU - Kim, Susan
AU - Chrischilles, Elizabeth
AU - Williams, David
N1 - Publisher Copyright:
© 2024 Varma et al.
PY - 2024/6
Y1 - 2024/6
N2 - Importance The frequency and characteristics of post-acute sequelae of SARS-CoV-2 infection (PASC) may vary by SARS-CoV-2 variant. Objective To characterize PASC-related conditions among individuals likely infected by the ancestral strain in 2020 and individuals likely infected by the Delta variant in 2021. Design Retrospective cohort study of electronic medical record data for approximately 27 million patients from March 1, 2020-November 30, 2021. Setting Healthcare facilities in New York and Florida. Participants Patients who were at least 20 years old and had diagnosis codes that included at least one SARS-CoV-2 viral test during the study period. Exposure Laboratory-confirmed COVID-19 infection, classified by the most common variant prevalent in those regions at the time. Main outcome(s) and measure(s) Relative risk (estimated by adjusted hazard ratio [aHR]) and absolute risk difference (estimated by adjusted excess burden) of new conditions, defined as new documentation of symptoms or diagnoses, in persons between 31-180 days after a positive COVID-19 test compared to persons without a COVID-19 test or diagnosis during the 31-180 days after the last negative test. Results We analyzed data from 560,752 patients. The median age was 57 years; 60.3% were female, 20.0% non-Hispanic Black, and 19.6% Hispanic. During the study period, 57,616 patients had a positive SARS-CoV-2 test; 503,136 did not. For infections during the ancestral strain period, pulmonary fibrosis, edema (excess fluid), and inflammation had the largest aHR, comparing those with a positive test to those without a COVID-19 test or diagnosis (aHR 2.32 [95% CI 2.09 2.57]), and dyspnea (shortness of breath) carried the largest excess burden (47.6 more cases per 1,000 persons). For infections during the Delta period, pulmonary embolism had the largest aHR comparing those with a positive test to a negative test (aHR 2.18 [95% CI 1.57, 3.01]), and abdominal pain carried the largest excess burden (85.3 more cases per 1,000 persons). Conclusions and relevance We documented a substantial relative risk of pulmonary embolism and a large absolute risk difference of abdomen-related symptoms after SARS-CoV-2 infection during the Delta variant period. As new SARS-CoV-2 variants emerge, researchers and clinicians should monitor patients for changing symptoms and conditions that develop after infection.
AB - Importance The frequency and characteristics of post-acute sequelae of SARS-CoV-2 infection (PASC) may vary by SARS-CoV-2 variant. Objective To characterize PASC-related conditions among individuals likely infected by the ancestral strain in 2020 and individuals likely infected by the Delta variant in 2021. Design Retrospective cohort study of electronic medical record data for approximately 27 million patients from March 1, 2020-November 30, 2021. Setting Healthcare facilities in New York and Florida. Participants Patients who were at least 20 years old and had diagnosis codes that included at least one SARS-CoV-2 viral test during the study period. Exposure Laboratory-confirmed COVID-19 infection, classified by the most common variant prevalent in those regions at the time. Main outcome(s) and measure(s) Relative risk (estimated by adjusted hazard ratio [aHR]) and absolute risk difference (estimated by adjusted excess burden) of new conditions, defined as new documentation of symptoms or diagnoses, in persons between 31-180 days after a positive COVID-19 test compared to persons without a COVID-19 test or diagnosis during the 31-180 days after the last negative test. Results We analyzed data from 560,752 patients. The median age was 57 years; 60.3% were female, 20.0% non-Hispanic Black, and 19.6% Hispanic. During the study period, 57,616 patients had a positive SARS-CoV-2 test; 503,136 did not. For infections during the ancestral strain period, pulmonary fibrosis, edema (excess fluid), and inflammation had the largest aHR, comparing those with a positive test to those without a COVID-19 test or diagnosis (aHR 2.32 [95% CI 2.09 2.57]), and dyspnea (shortness of breath) carried the largest excess burden (47.6 more cases per 1,000 persons). For infections during the Delta period, pulmonary embolism had the largest aHR comparing those with a positive test to a negative test (aHR 2.18 [95% CI 1.57, 3.01]), and abdominal pain carried the largest excess burden (85.3 more cases per 1,000 persons). Conclusions and relevance We documented a substantial relative risk of pulmonary embolism and a large absolute risk difference of abdomen-related symptoms after SARS-CoV-2 infection during the Delta variant period. As new SARS-CoV-2 variants emerge, researchers and clinicians should monitor patients for changing symptoms and conditions that develop after infection.
UR - http://www.scopus.com/inward/record.url?scp=85195439417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195439417&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0282451
DO - 10.1371/journal.pone.0282451
M3 - Article
C2 - 38843159
AN - SCOPUS:85195439417
SN - 1932-6203
VL - 19
JO - PloS one
JF - PloS one
IS - 6 June
M1 - e0282451
ER -